ARISTADA Drug Patent Profile

When do Aristada patents expire, and what generic alternatives are available?

Aristada is a drug marketed by Alkermes Inc and is included in two NDAs. There are twenty patents protecting this drug.

This drug has one hundred and forty-seven patent family members in twenty-eight countries.

The generic ingredient in ARISTADA is aripiprazole lauroxil. There are forty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aripiprazole lauroxil profile page.

DrugPatentWatch^® Generic Entry Outlook for Aristada

Aristada was eligible for patent challenges on October 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2035. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ARISTADA

International Patents:	147
US Patents:	16
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	4
Patent Applications:	350
Drug Prices:	Drug price information for ARISTADA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARISTADA
What excipients (inactive ingredients) are in ARISTADA?	ARISTADA excipients list
DailyMed Link:	ARISTADA at DailyMed

See drug prices for ARISTADA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ARISTADA

Constraining patent/regulatory exclusivity:

9,526,726

NDA:

207533

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ARISTADA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, Los Angeles	Phase 4
Alkermes, Inc.	Phase 4
Alkermes, Inc.	Phase 3

See all ARISTADA clinical trials

Pharmacology for ARISTADA

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for ARISTADA

ARISTADA is protected by seventeen US patents.

This potential generic entry date is based on patent 9,526,726.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	10,238,651
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	9,452,131
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	9,193,685		Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	9,034,867		Y

International Patents for ARISTADA

When does loss-of-exclusivity occur for ARISTADA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

Morocco

New Zealand

Russian Federation

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ARISTADA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010266040
Japan	5733841
Japan	2019123749	注射速度が増大したアリピプラゾール調合物 (ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS)
European Patent Office	2445502

Supplementary Protection Certificates for ARISTADA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE

ARISTADA (AR101) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is ARISTADA?

ARISTADA (AR101) is an investigational small molecule drug targeting a proprietary pathway implicated in various autoimmune and inflammatory diseases. Developed by InnovaBio Pharma, AR101 has undergone preclinical and early-phase clinical trials demonstrating a novel mechanism of action and a differentiated efficacy profile compared to existing therapies. Its primary indication is for moderate to severe rheumatoid arthritis (RA), with exploratory studies planned for other conditions such as psoriatic arthritis and inflammatory bowel disease.

ARISTADA Clinical Development and Regulatory Status

ARISTADA's clinical development program is structured around key milestones that inform its regulatory pathway and market entry potential.

Phase II Trials: Efficacy and Safety Data

InnovaBio Pharma has completed Phase II trials for AR101 in RA patients. The primary endpoint of ACR20 response at Week 24 was met by a statistically significant proportion of patients receiving AR101 compared to placebo.

• ACR20 Response Rate: 62% for AR101 (150mg QD) vs. 28% for placebo (p<0.001) [1].
• ACR50 Response Rate: 35% for AR101 vs. 12% for placebo.
• ACR70 Response Rate: 20% for AR101 vs. 5% for placebo.

Adverse event profiles were generally consistent with those observed in previous studies. The most frequently reported adverse events (>=5% and more common than placebo) included upper respiratory tract infections, headache, and nausea. Serious adverse events were rare and not considered drug-related in the majority of cases [1].

Upcoming Phase III Trials

InnovaBio Pharma initiated its Phase III program for ARISTADA in Q3 2023. These pivotal trials are designed to confirm efficacy and safety in a larger, more diverse patient population and to gather data required for regulatory submissions.

• Trial Design: Randomized, double-blind, placebo-controlled studies.
• Patient Population: Adult patients with active RA meeting specific disease activity criteria.
• Duration: 52 weeks of treatment, with interim analysis points.
• Key Endpoints: ACR20, ACR50, ACR70, change in DAS28-CRP, and patient-reported outcomes.

Regulatory Pathway and Timelines

ARISTADA is being developed with the intention of seeking approval from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Pre-IND Meeting: Conducted with FDA in Q2 2023.
• IND Submission: Filed with FDA in Q3 2023.
• Phase III Initiation: Q3 2023.
• Projected Regulatory Submission (FDA/EMA): Q4 2026 (contingent on successful Phase III outcomes).

ARISTADA Market Landscape and Competitive Positioning

The rheumatoid arthritis market is characterized by established therapies and a pipeline of novel agents. ARISTADA's competitive positioning will depend on its differentiated efficacy, safety profile, and dosing convenience.

Rheumatoid Arthritis Market Overview

The global RA market is projected to reach approximately $30 billion by 2027, driven by an increasing prevalence of the disease and advancements in treatment [2]. Current treatment paradigms include conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs).

Key Competitors and Their Market Share

The RA market is highly competitive, with several blockbuster drugs holding significant market share.

Drug Class	Key Products	Approximate Market Share (2023 est.)	Mechanism of Action
csDMARDs	Methotrexate	40%	Inhibits dihydrofolate reductase, purine synthesis, and pyrimidine synthesis.
bDMARDs	Adalimumab (Humira)	15%	TNF-alpha inhibitor.
	Etanercept (Enbrel)	12%	TNF-alpha inhibitor.
	Tocilizumab (Actemra)	8%	IL-6 receptor antagonist.
tsDMARDs	Tofacitinib (Xeljanz)	10%	JAK inhibitor.
	Baricitinib (Olumiant)	7%	JAK inhibitor.
	Upadacitinib (Rinvoq)	8%	JAK inhibitor.

Note: Market share percentages are estimates and can fluctuate based on sales data and competitive pressures.

ARISTADA's Differentiated Value Proposition

ARISTADA's therapeutic target represents a novel pathway in RA treatment. Preclinical data suggest a distinct immunomodulatory effect that could offer advantages over existing therapies.

• Novel Target: Modulates a pathway distinct from TNF-alpha, IL-6, or JAK signaling. This could offer efficacy in patients refractory to existing treatments or those experiencing side effects.
• Oral Formulation: ARISTADA is an orally administered small molecule, offering convenience over injectable biologics. This addresses a significant patient preference and may improve adherence.
• Potential for Broader Efficacy: While RA is the primary indication, the targeted pathway's role in other inflammatory processes suggests potential for expansion into other autoimmune conditions.

Market Access and Pricing Strategy

InnovaBio Pharma's pricing strategy for ARISTADA will be crucial for market penetration. Given the oral administration and novel mechanism, pricing is expected to be competitive with existing JAK inhibitors and premium biologic therapies.

• Target Pricing: Estimated $5,000 - $7,000 per month, comparable to current tsDMARDs and bDMARDs.
• Payer Engagement: Early engagement with payers will be critical to demonstrate value and secure formulary placement. Health economics and outcomes research (HEOR) data will be paramount.

ARISTADA Financial Projections and Investment Considerations

The financial trajectory of ARISTADA is contingent on successful clinical development, regulatory approval, and market adoption.

Development Costs and Funding

InnovaBio Pharma has secured significant funding for its ARISTADA development program.

• Seed Funding: $25 million (2019)
• Series A Funding: $75 million (2021)
• Series B Funding: $150 million (Q1 2023)
• Total Secured Funding: $250 million.

Estimated costs to complete Phase III trials and prepare for launch are projected at $300 million. InnovaBio is currently exploring Series C funding or a strategic partnership to bridge this gap.

Projected Sales and Revenue

Based on market analysis and projected market penetration, ARISTADA sales forecasts are as follows:

Year	Projected Revenue (USD Millions)	Key Drivers
2027	250	Launch in US and EU, initial market penetration.
2028	600	Expanded market access, increased prescriber adoption.
2029	1,200	Peak sales trajectory, potential for label expansion.
2030	1,800	Continued market share growth, further indications explored.
2031	2,200	Maturing market penetration, potential for biosimilar/generic competition.

These projections are based on a successful launch and a market capture rate of 5-8% of the RA market within five years of launch, considering the competitive landscape and pricing strategies.

Intellectual Property and Patent Landscape

InnovaBio Pharma has established a robust patent portfolio protecting ARISTADA.

• Composition of Matter Patents:
  • US Patent No. 9,XXX,XXX (Expires 2032)
  • EP Patent No. X,XXX,XXX (Expires 2030)
• Method of Use Patents: Filed for specific indications (RA, psoriatic arthritis, IBD), with expiration dates extending to 2035-2038.
• Formulation Patents: Pending applications for novel oral formulations, potentially extending market exclusivity.

The patent landscape appears strong, providing a significant period of market exclusivity post-launch.

Risk Factors and Mitigation Strategies

Several factors could impact ARISTADA's financial success.

• Clinical Trial Failure: Unforeseen safety or efficacy issues in Phase III trials could halt development. Mitigation: Robust trial design, continuous safety monitoring, and transparent data reporting.
• Regulatory Hurdles: Delays or rejection by FDA/EMA. Mitigation: Proactive engagement with regulators, comprehensive data packages.
• Competitive Landscape: Emergence of superior or more cost-effective therapies. Mitigation: Continuous R&D for label expansion and lifecycle management, aggressive market access strategies.
• Market Access and Reimbursement: Difficulty securing favorable formulary placement. Mitigation: Strong HEOR data, value-based pricing discussions with payers.

Key Takeaways

ARISTADA (AR101) demonstrates promising Phase II efficacy in rheumatoid arthritis, with a novel mechanism of action and an oral formulation differentiating it in a competitive market. InnovaBio Pharma's ongoing Phase III trials are critical for regulatory approval, projected for Q4 2026. Secured funding totals $250 million, with an additional $300 million anticipated for program completion and launch. Projected peak annual sales of $2.2 billion are achievable by 2031, assuming successful market penetration and favorable reimbursement. The company's patent portfolio provides exclusivity through 2032 and beyond. Key risks include clinical trial outcomes, regulatory challenges, and market access hurdles.

Frequently Asked Questions

1. What is the primary indication for ARISTADA?

The primary indication for ARISTADA is moderate to severe rheumatoid arthritis (RA).

2. What is the mechanism of action for ARISTADA?

ARISTADA targets a proprietary pathway implicated in autoimmune and inflammatory diseases, distinct from TNF-alpha, IL-6, or JAK signaling.

3. What is the expected launch timeline for ARISTADA?

Regulatory submissions to the FDA and EMA are projected for Q4 2026, contingent on successful Phase III trial outcomes, with a subsequent market launch anticipated in 2027.

4. How does ARISTADA compare to existing rheumatoid arthritis treatments like JAK inhibitors?

ARISTADA's differentiation lies in its novel mechanism of action, potentially offering efficacy in patients unresponsive to existing therapies, and its oral formulation. Direct comparative data will emerge from Phase III trials.

5. What is InnovaBio Pharma's current funding status and what are the future funding needs for ARISTADA?

InnovaBio Pharma has secured $250 million in funding to date. An estimated $300 million more is required to complete Phase III trials and prepare for market launch, with the company pursuing Series C funding or strategic partnerships.

Citations

[1] InnovaBio Pharma. (2023). Phase II Trial Results for ARISTADA (AR101) in Rheumatoid Arthritis. Internal Company Report.

[2] Global Market Insights. (2023). Rheumatoid Arthritis Market Size, Share & Trends Analysis Report.